Mounjaro and Libido: What Does the Evidence Tell Us?

Why people notice libido changes — and what's actually causing them

One misconception worth setting aside gently: many people assume any change in sex drive on Mounjaro is a direct pharmacological effect, like a drug acting on the brain. That's not what the evidence shows. The licensed prescribing information for tirzepatide does not list altered libido as a recognised side effect. What the research does show is that meaningful weight loss changes the body's hormonal environment substantially, and sex drive sits squarely inside that environment.

Testosterone, for example, is often suppressed in people carrying significant excess weight, partly because adipose tissue converts it into oestrogen. As weight falls on treatment, this conversion lessens, and free testosterone can rise in both men and women. Similarly, oestrogen levels in women tend to regulate more predictably as metabolic health improves. For a detailed account of the hormonal picture, the tirzepatide overview on this site covers the mechanism in full. The NHS patient information for tirzepatide, available at nhs.uk/medicines/tirzepatide, is the clearest summary of effects to expect.

The upshot is that libido changes during Mounjaro treatment are mostly downstream of what the medicine does to your weight and metabolism, not a direct action on sexual function. That distinction matters, because it shapes how you think about any change you notice.

The short-term picture: when libido dips early on

In the first weeks, particularly around dose increases, many people feel genuinely rough. Nausea, fatigue, low appetite and occasional dizziness are the most common early experiences. It would be surprising if sex drive were unaffected. Feeling exhausted and queasy is not a mental state that encourages intimacy, regardless of any hormonal effect.

This phase is real and worth acknowledging, but it is also typically temporary. The gastrointestinal side effects of tirzepatide are well-documented and tend to peak shortly after each dose step before settling as the body adjusts. For more on managing that adjustment period, the page on how Mounjaro affects libido specifically goes into greater practical detail.

The key point for decision-making: a short-term dip in sex drive during the early titration phase is not a signal that something has gone permanently wrong. For most people, this resolves once the dose stabilises and energy levels recover. If it does not, that is a conversation to have with your prescriber, not something to work around silently.

The longer-term picture: when libido improves

Across the SURMOUNT-1 trial, participants on tirzepatide achieved substantial average weight loss over 72 weeks, published in the New England Journal of Medicine. Weight loss of that magnitude changes how people feel in their bodies, how they move, and (critically) how they feel about themselves. Several studies of weight loss interventions (independent of the specific medicine used) consistently find improvements in sexual function scores, desire and satisfaction as BMI falls.

For men, the testosterone story is especially relevant. Clinical data on GLP-1-related weight loss in men with obesity shows meaningful increases in free testosterone, which is closely linked to libido, energy and mood. The experience of Mounjaro and libido in men is explored separately if that angle is relevant to you. For women, the picture is covered on the Mounjaro libido and women page.

It is also worth noting that for people who experience improved energy, better sleep (often a downstream benefit of weight loss) and reduced joint discomfort, the overall quality-of-life shift can be significant. Libido rarely exists in isolation from the rest of how you feel.

Making the decision: what to weigh up before starting treatment

If libido is a concern going into treatment (whether you are worried about suppression or hoping for improvement) the honest answer is that you cannot know in advance exactly how you will respond. What the evidence does support is that the short-term risk of a temporary dip is real but usually time-limited, and the longer-term potential for improvement is genuinely plausible for most people who achieve meaningful weight reduction.

Before starting, it is worth being honest with your prescriber about any existing sexual health concerns, hormonal conditions, or medications that affect libido (certain antidepressants, for instance). These factors change the picture. If you are also taking other medicines alongside treatment, our page on using Laxido alongside Mounjaro is one example of the practical guidance available on combining medications. You may also want to explore what Mounjaro costs privately in the UK if you are considering this route, as pricing and what is included vary significantly between providers. The MHRA's published guidance on GLP-1 medicines, available on GOV.UK, covers what is and is not known about effects beyond weight loss for anyone wanting the regulatory perspective.

A question our prescribers hear regularly is whether starting treatment will affect an existing relationship or sense of intimacy. It is a reasonable thing to raise. The consultation exists precisely for questions like that, not just clinical data, but what matters to you personally. If you would like to read a broader overview before speaking to anyone, our full Mounjaro information page is a good place to start. If you would like to speak with a clinician about how Mounjaro fits your situation, starting a free consultation with our prescribers is the straightforward next step.